Market News AIOpen the app

Purple Biotech shared promising early results for its cancer drug IM1240 at the EORTC-NCI-AACR Symposium.

TrialRead the original at globenewswire.com
Good for PPBT

Purple Biotech's IM1240 showed anti-cancer activity in preclinical models and less cytokine release in primates, supporting the drug program. The tests were not in people, and a prior report cited a $1.0 million quarterly loss, but these findings support the program's promise.

PPBT · Purple Biotech Ltd.

AI read · Good for PPBT

The AI's read

The cap is designed to limit T-cell activity throughout the body while allowing it inside tumors. Activity in several cancer models and lower cytokine release in primates support this approach. These tests were not in people, so they do not show whether IM1240 helps patients.

Get alerts for PPBT

Follow Purple Biotech Ltd. (PPBT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PPBT
Free on the App Store and Google Play, or on the web.